| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| Selinexor (KPT-330); Selinexor (KPT-330) | CFN60293 | 1393477-72-9 | C17H11F6N7O = 443.31 | 5mg | QQ客服：1457312923 |
| NMS-873; NMS-873 | CFN60294 | 1418013-75-8 | C27H28N4O3S2 = 520.67 | 5mg | QQ客服：3257982914 |
| SAR131675; SAR131675 | CFN60295 | 1433953-83-3 | C18H22N4O4 = 358.39 | 5mg | QQ客服：1457312923 |
| Ravoxertinib (GDC-0994); Ravoxertinib (GDC-0994) | CFN60296 | 1453848-26-4 | C21H18ClFN6O2 = 439.85 | 5mg | QQ客服：215959384 |
| 阿糖胞苷; Cytarabine | CFN60297 | 147-94-4 | C9H13N3O5 = 243.22 | 5mg | QQ客服：215959384 |
| 泰诺福韦; Tenofovir | CFN60298 | 147127-20-6 | C9H14N5O4P = 287.21 | 5mg | QQ客服：3257982914 |
| AG-1478 (Tyrphostin AG-1478); AG-1478 (Tyrphostin AG-1478) | CFN60299 | 153436-53-4 | C16H14ClN3O2 = 315.75 | 5mg | QQ客服：215959384 |
| 阿比特龙; Abiraterone | CFN60300 | 154229-19-3 | C24H31NO = 349.51 | 5mg | QQ客服：3257982914 |
| NU7026; NU7026 | CFN60301 | 154447-35-5 | C17H15NO3 = 281.31 | 5mg | QQ客服：1413575084 |
| Zosuquidar (LY335979) 3HCl; Zosuquidar (LY335979) 3HCl | CFN60302 | 167465-36-3 | C32H31F2N3O2.3HCl = 636.99 | 5mg | QQ客服：3257982914 |
| 阿瑞吡坦; Aprepitant | CFN60303 | 170729-80-3 | C23H21F7N4O3 = 534.43 | 5mg | QQ客服：1413575084 |
| 枸橼酸西地那非; Sildenafil Citrate | CFN60304 | 171599-83-0 | C22H30N6O4S.C6H8O7 = 666.7 | 5mg | QQ客服：1413575084 |
| PP1; PP1 | CFN60305 | 172889-26-8 | C16H19N5 = 281.36 | 5mg | QQ客服：2056216494 |
| 卡巴他赛; Cabazitaxel | CFN60306 | 183133-96-2 | C45H57NO14 = 835.93 | 20mg | QQ客服：1413575084 |
| Bay 11-7085; Bay 11-7085 | CFN60307 | 196309-76-9 | C13H15NO2S = 249.33 | 5mg | QQ客服：2159513211 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)